Overall, the combination of mineralocorticoid receptor antagonists and sodium glucose cotransporter 2 inhibitors presents a novel therapeutic strategy for managing atrial fibrillation by targeting both the underlying pathophysiological mechanisms and associated comorbidities [109,110]. Here, NR3C2 is linked to atrial fibrillation.